Palisade Bio Inc PALI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
-
Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
-
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
-
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
-
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
-
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
-
Palisade Bio to Participate in Upcoming Investor Conferences
-
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
Trading Information
- Previous Close Price
- $1.35
- Day Range
- $1.28–1.37
- 52-Week Range
- $1.28–2.86
- Bid/Ask
- $1.30 / $1.38
- Shares Outstanding
- 174.27M
- Market Cap
- $231.78M
- Volume/Avg
- 1M / 3M
Key Statistics
- Price/Earnings (Normalized)
- 1.95
- Price/Sales
- 421.69
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 14
- Website
- https://www.palisadebio.com
Valuation
|
Metric
|
PALI
|
|---|---|
Price/Earnings (Normalized) | 1.95 |
Price/Book Value | 1.90 |
Price/Sales | 421.69 |
Price/Cash Flow | — |
Price/Earnings
PALI
Financial Strength
|
Metric
|
PALI
|
|---|---|
Quick Ratio | 23.96 |
Current Ratio | 24.26 |
Interest Coverage | −3,991.63 |
Quick Ratio
PALI
Profitability
|
Metric
|
PALI
|
|---|---|
Return on Assets (Normalized) | −23.30% |
Return on Equity (Normalized) | −24.77% |
Return on Invested Capital (Normalized) | −24.72% |
Return on Assets
PALI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&Ts%S&k | LOCK|JkHYy | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^r&M!& | LOCK|jPCn | $83B | |||
| Moderna Inc
MRNA
| LOCK|H?@kg$^ | LOCK|@T | $80B | |||
| argenx SE ADR
ARGX
| LOCK|<y^VC!N | LOCK|%kc | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|x@q<B> | LOCK|@d | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%vVz#d | LOCK|C@<^p | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@m?wp!! | LOCK|S%># | $28B | |||
| Incyte Corp
INCY
| LOCK|zRZdcN! | LOCK|&c | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|>zL@!j | LOCK|Yx | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&!pSvy$ | LOCK|Tx! | $14B |
United States